A Bengaluru-based biotech firm has developed the world’s first rapid snake venom detection kit that delivers results from a single drop of blood in approximately two minutes, promising to transform emergency care for the 58,000 Indians who die annually from snakebite envenoming. The lateral flow immunoassay, created by Bhat Biotech India Private Limited under Chairman Dr. Shama Bhat, has received Drug Control approval and will soon reach ASHA workers, primary health centers, and ambulances across snake-prone regions.
The Clinical Void
Snakebite envenoming remains India’s most neglected tropical disease crisis. Current practice forces clinicians to wait for systemic symptoms—neurotoxic paralysis or hemorrhagic coagulopathy—before administering antivenom, often missing the critical “golden hour”. This diagnostic uncertainty leads to two dangerous outcomes: delayed treatment for true envenomations, and unnecessary antivenom administration for dry bites, exposing patients to serum sickness and anaphylaxis while wasting a costly biological product. Dr. Javed Ali, a pharmaceutical consultant, notes that rural primary health centers face an “diagnostic dilemma” where expensive antivenom and its adverse effects create therapeutic paralysis.
How the Kit Works
The device functions like a pregnancy test: two drops of blood are placed on a nitrocellulose strip impregnated with gold nanoparticle-conjugated antibodies specific to conserved venom epitopes. Capillary action draws the sample across test lines coated with anti-venom antibodies. Two lines indicate venom detection; one control line confirms a non-venomous bite. Dr. Shama Bhat’s team claims 100% accuracy in detecting both hemotoxic and neurotoxic venoms, though independent validation data remains unpublished.
The technology builds on a 2016 Indian Institute of Technology-Bombay prototype that used gold nanoparticles to detect cobra and Russell’s viper venom, but required 20 minutes and laboratory equipment. Bhat Biotech’s innovation reduces test duration to two minutes and eliminates instrumentation, enabling field deployment.
Regulatory and Validation Status
The kit received approval from India’s Central Drugs Standard Control Organization (CDSCO) under the Medical Devices Rules, 2017, classifying it as a Class C in vitro diagnostic. However, clinical validation questions persist. While Dr. Bhat’s LinkedIn announcement cites “100% accuracy,” peer-reviewed studies are absent from scientific literature. Mani Ratnam Puli, a pharmacology specialist, questioned whether the kit can differentiate venom types—a critical factor since antivenom choice depends on whether toxins are neurotoxic (cobras, kraits) or hemotoxic (vipers). The current version appears to detect venom presence rather than immunotype, though a 2016 patent by Indian researchers described a one-minute test capable of distinguishing neurotoxin from hemotoxin.
Implementation Challenges
India’s National Action Plan for Prevention and Control of Snakebite Envenoming (NAPSE), launched in March 2024, aims to halve snakebite deaths by 2030 by strengthening regional venom centers and improving antivenom quality. The plan explicitly prioritizes “enhancing anti-snake venom (ASV) distribution and quality” but makes no mention of rapid diagnostics, revealing a policy blind spot.
Field deployment faces logistical hurdles. Venom enters systemic circulation at variable rates depending on bite depth and location, meaning a two-minute test might yield false negatives if performed too early. Zemenu Binalfew, a hospital coordinator, appropriately asked about validation sample size and real-world performance across India’s diverse snake species.
The Broader Impact
If validated, the kit could reduce India’s antivenom wastage, estimated at 20-30% of vials administered unnecessarily. Bhat Biotech’s innovation exemplifies “Make in India” biotechnology addressing a neglected tropical disease, potentially positioning the country as a global leader in snakebite diagnostics. The company, founded by Dr. Bhat in Mangalore, has previously introduced pregnancy and dengue diagnostic kits, bringing 35 years of biotechnology expertise to this breakthrough.Rithvisha Kiran
